All stocks / EMMA
Emmaus Life Sciences, Inc. EMMA
Emmaus Life Sciences (EMMA): convertible notes mentioned in an 8-K in December 2025, a late 10-Q notice in November 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- EMMAUS LIFE SCIENCES INC NEW
- Market tier
- OTCQB
- Trading status
- Active
- Last trade
- Nov 13
- Website
- ir.emmausmedical.com/
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Revenue
- $12,453,000
- Net loss
- ($7,492,000)
It spends more than it earns
Under strainCustomers paid it $12.5 million in the year. It lost $7.5 million. For every $1 that came in, about $1.60 went out.
- Cash and cash equivalents
- $2,127,000
- Net cash used in operating activities
- ($11,000)
It has cash for a while
SteadyIt had $2.1 million in the bank and used about $917 a month. At that pace the money lasts about 2320 months unless it borrows or sells more shares.
- Total assets
- $21,436,000
- Total liabilities
- $85,044,000
It owes more than it owns
Under strainEverything the company owns adds up to $21.4 million. Its debts and unpaid bills add up to $85 million. That is about $3.97 owed for every $1 owned.
What this adds up to
2 of 3 checks show strain. It spends more than it earns. It owes more than it owns. These are facts from the company's own reports, not a recommendation.
Signals
Filed NT 10-Q on 2026-11-16: notice that a periodic report is late.
Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record
Estimated float about 69,498,096 shares as of 2026-08-11: 70,188,263 outstanding minus 690,167 held by 1 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
8-K filed 2025-12-22 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about EMMA
Does EMMA file reports with the SEC?
Yes. Emmaus Life Sciences files with the SEC under company number 0000822370. The most recent filing we hold is a NT 10-Q dated 2026-11-16.
Source recordHow many EMMA shares are outstanding?
70,188,263 shares as of 2026-08-11, as reported to the SEC.
Source recordHas EMMA filed reports late?
Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-Q on 2026-11-16. A notice means a report was not ready on time; check whether the report followed.
Source recordWho runs Emmaus Life Sciences?
Officers named in its insider filings: Willis C Lee (CEO).
Source recordIs Emmaus Life Sciences making money?
Customers paid it $12.5 million in the year. It lost $7.5 million. For every $1 that came in, about $1.60 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record